Adult granulosa cell tumours (GCT): Clinicopathological outcomes including FOXL2 mutational status and expression

被引:27
作者
Rosario, Roseanne [1 ]
Wilson, Michelle [2 ]
Cheng, Wei-Tzu [1 ]
Payne, Kathryn [3 ]
Cohen, Paul A. [4 ]
Fong, Peter [2 ]
Shelling, Andrew N. [1 ]
机构
[1] Univ Auckland, Dept Obstet & Gynaecol, Auckland 1, New Zealand
[2] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand
[3] Auckland City Hosp, Dept Pathol, Auckland, New Zealand
[4] Univ Western Australia, Sch Womens & Infants Hlth, Nedlands, WA 6009, Australia
关键词
Granulosa cell tumour; FOXL2; Prognostic marker; Diagnostic tool; FFPE; TRANSCRIPTION FACTOR FOXL2; CORD-STROMAL TUMORS; PROGNOSTIC-FACTORS; FOLLOW-UP; OVARY; EVOLUTION; SURVIVAL;
D O I
10.1016/j.ygyno.2013.08.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The aim of this research was to use nucleic acid's isolated from formalin-fixed paraffin-embedded (FFPE) tissue to investigate the diagnostic potential and prognostic significance of FOXL2 in adult-type GCTs, particularly as a marker of identifying early stage patients that are likely to relapse. Methods. We performed a retrospective review of GCT patients referred to the Auckland Gynae-Oncology Multidisciplinary Team from 1955 to 2012. Baseline characteristics, clinical course, histopathology and survival data was recorded. Using nucleic acids extracted from FFPE tumour blocks, FOXL2 mutation status and expression was determined by DNA sequencing and RT-qPCR, respectively, and correlated with clinical data. Results. 57 adult GCT patients were identified, however FFPE tumour blocks were available for only 37 of these patients. Sequencing results confirmed the presence of the FOXL2 mutation in 70% of patients. FOXL2 mutation positive adult tumours showed a trend towards higher FOXL2 expression than wildtype adult tumours, particularly in stage I patients (p = 0.051). In addition, patients with homozygous FOXL2 mutations had a significantly higher relapse rate (p = 0.04). There was no significant correlation between FOXL2 mutation status or FOXL2 expression and any other clinical variables. Conclusions. FFPE tumour blocks are a valuable resource of molecular information, especially when studying rare tumours such as GCTs. The FOXL2 mutation appears to have some diagnostic potential, however additional work in a larger cohort needs to be completed to confirm the prognostic significance of this gene mutation, and its expression. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:325 / 329
页数:5
相关论文
共 37 条
  • [1] Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes
    Amsterdam, A
    Selvaraj, N
    [J]. ENDOCRINE REVIEWS, 1997, 18 (04) : 435 - 461
  • [2] Prognostic factors of ovarian granulosa cell tumor:: a study of 35 patients and review of the literature
    Auranen, A.
    Sundstrom, J.
    Ijas, J.
    Grenman, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (05) : 1011 - 1018
  • [3] Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase
    Benayoun, Berenice A.
    Georges, Adrien B.
    L'Hote, David
    Andersson, Noora
    Dipietromaria, Aurelie
    Todeschini, Anne-Laure
    Caburet, Sandrine
    Bazin, Claude
    Anttonen, Mikko
    Veitia, Reiner A.
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 (09) : 1673 - 1686
  • [4] Functional Exploration of the Adult Ovarian Granulosa Cell Tumor-Associated Somatic FOXL2 Mutation p.Cys134Trp (c.402C>G)
    Benayoun, Berenice A.
    Caburet, Sandrine
    Dipietromaria, Aurelie
    Georges, Adrien
    D'Haene, Barbara
    Pandaranayaka, P. J. Eswari
    L'Hote, David
    Todeschini, Anne-Laure
    Krishnaswamy, Sankaran
    Fellous, Marc
    De Baere, Elfride
    Veitia, Reiner A.
    [J]. PLOS ONE, 2010, 5 (01):
  • [5] PROGNOSTIC FACTORS IN GRANULOSA-CELL TUMORS
    BJORKHOLM, E
    SILFVERSWARD, C
    [J]. GYNECOLOGIC ONCOLOGY, 1981, 11 (03) : 261 - 274
  • [6] The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
    Bustin, Stephen A.
    Benes, Vladimir
    Garson, Jeremy A.
    Hellemans, Jan
    Huggett, Jim
    Kubista, Mikael
    Mueller, Reinhold
    Nolan, Tania
    Pfaffl, Michael W.
    Shipley, Gregory L.
    Vandesompele, Jo
    Wittwer, Carl T.
    [J]. CLINICAL CHEMISTRY, 2009, 55 (04) : 611 - 622
  • [7] Prognostic factors responsible for survival in sex cord stromal tumors of the ovary - A multivariate analysis
    Chan, JK
    Zhang, M
    Kaleb, V
    Loizzi, V
    Benjamin, J
    Vasilev, S
    Osann, K
    DiSaia, PJ
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 204 - 209
  • [8] Evolution and expression of FOXL2
    Cocquet, J
    Pailhoux, E
    Jaubert, F
    Servel, N
    Xia, X
    Pannetier, M
    De Baere, E
    Messiaen, L
    Cotinot, C
    Fellous, M
    Veitia, RA
    [J]. JOURNAL OF MEDICAL GENETICS, 2002, 39 (12) : 916 - 921
  • [9] Management of ovarian stromal cell tumors
    Colombo, Nicoletta
    Parma, Gabriella
    Zanagnolo, Vanna
    Insinga, Alessandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) : 2944 - 2951
  • [10] The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome
    Crisponi, L
    Deiana, M
    Loi, A
    Chiappe, F
    Uda, M
    Amati, P
    Bisceglia, L
    Zelante, L
    Nagaraja, R
    Porcu, S
    Ristaldi, MS
    Marzella, R
    Rocchi, M
    Nicolino, M
    Lienhardt-Roussie, A
    Nivelon, A
    Verloes, A
    Schlessinger, D
    Gasparini, P
    Bonneau, D
    Cao, A
    Pilia, G
    [J]. NATURE GENETICS, 2001, 27 (02) : 159 - 166